PREDICTING THE EFFICACY OF INCLISIRAN ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: PRIMARY RESULTS OF THE IN SILICO SIRIUS TRIAL

被引：0

作者：

Angoulvant, Denis ^{[1
]}

Amarenco, Pierre ^{[2
]}

Bastien, Alexandre ^{[3
]}

Bechet, Emmanuelle ^{[4
]}

Boccara, Franck ^{[5
]}

Boissel, Jean-Pierre ^{[4
]}

Cariou, Bertrand ^{[6
]}

Courcelles, Eulalie ^{[4
]}

Diatchenko, Alizee ^{[4
]}

Filipovics, Anne ^{[3
]}

Granjeon-Noriot, Solene ^{[4
]}

Kahoul, Riad ^{[4
]}

Mahe, Guillaume ^{[7
]}

Peyronnet, Emmanuel ^{[4
]}

Portal, Lolita ^{[3
]}

Porte, Solene ^{[4
]}

Wang, Yishu ^{[4
]}

Steg, Philippe Gabriel ^{[8
]}

机构：

[1] CHRU Tours, Cardiol, Tours, France

[2] Hop Xavier Bichat, Neurol, APHP, Paris, France

[3] Novartis, Rueil Malmaison, France

[4] Novadiscovery, Lyon, France

[5] St Antoine Res Ctr, Cardiol, Paris, France

[6] Inst Thorax, Endocrinol, Nantes, France

[7] CHU Rennes, Vasc Med Unit, Rennes, France

[8] APHP Bichat Hosp, Cardiol, Paris, France

来源：

ATHEROSCLEROSIS | 2024年 / 395卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SaaG169

引用

页数：1

共 50 条

[31] Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
McGuire, Darren K.
Busui, Rodica P.
Deanfield, John
Inzucchi, Silvio E.
Mann, Johannes F. E.
Marx, Nikolaus
Mulvagh, Sharon L.
Poulter, Neil
Engelmann, Mads D. M.
Hovingh, G. Kees
Ripa, Maria Sejersten
Gislum, Mette
Brown-Frandsen, Kirstine
Buse, John B.
DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1932 - 1941
[32] Therapy in patients at high risk for atherosclerotic cardiovascular disease -: From biological efficacy to disappointing clinical outcomes
Fainaru, M
FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 : S186 - S186
[33] Cost-effectiveness of clopidogrel addition to aspirin to prevent cardiovascular events in patients with established cardiovascular disease: results from the CHARISMA trial
Bakhai, A.
Chen, J.
Schneider, E.
Bhatt, D. L.
De Pouvourville, G.
Willich, S. N.
Caro, J.
Hacke, W.
Fox, K. A. A.
Cohen, D. J.
EUROPEAN HEART JOURNAL, 2007, 28 : 858 - 858
[34] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kaku, Kohei
Lee, Jisoo
Mattheus, Michaela
Kaspers, Stefan
George, Jyothis
Woerle, Hans-Juergen
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
Strivay, M.
Vereecken, G.
Keymeulen, B.
Lamkanfi, F.
CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
[35] Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
Hageman, Steven H. J.
McKay, Ailsa J.
Ueda, Peter
Gunn, Laura H.
Jernberg, Tomas
Hagstrom, Emil
Bhatt, Deepak L.
Steg, Ph Gabriel
Lall, Kristi
Magi, Reedik
Gynnild, Mari Nordbo
Ellekjaer, Hanne
Saltvedt, Ingvild
Tunon, Jose
Mahillo, Ignacio
Acena, Alvaro
Kaminski, Karol
Chlabicz, Malgorzata
Sawicka, Emilia
Tillman, Taavi
McEvoy, John W.
Di Angelantonio, Emanuele
Graham, Ian
De Bacquer, Dirk
Ray, Kausik K.
Dorresteijn, Jannick A. N.
Visseren, Frank L. J.
EUROPEAN HEART JOURNAL, 2022, 43 (18) : 1715 - 1727
[36] Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
Li, Sha
Liu, Hui-Hui
Guo, Yuan-Lin
Zhu, Cheng-Gang
Wu, Na-Qiong
Xu, Rui-Xia
Dong, Qian
Qian, Jie
Dou, Ke-Fei
Li, Jian-Jun
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[37] Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Green, Jennifer B.
Bethel, M. Angelyn
Paul, Sanjoy K.
Ring, Arne
Kaufman, Keith D.
Shapiro, Deborah R.
Califf, Robert M.
Holman, Rury R.
AMERICAN HEART JOURNAL, 2013, 166 (06) : 983 - U83
[38] Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial
Chen, Jersey
Shi, Chunxue
Mahoney, Elizabeth M.
Dunn, Elizabeth Schneider
Rinfret, Stephane
Caro, J. Jaime
O'Brien, Judith
El-Hadi, Wissam
Bhatt, Deepak L.
Topol, Eric J.
Cohen, David J.
CANADIAN JOURNAL OF CARDIOLOGY, 2011, 27 (02) : 222 - 231
[39] Statin Use and Atherosclerotic Cardiovascular Events in Patients With Established Atherosclerotic Heart Disease and End-stage Renal Disease on Dialysis
Shavadia, Jay S.
Wilson, Jonathan A.
Edmonston, Daniel
Platt, Alyssa
Ephraim, Patti
Hall, Rasheeda
Goldstein, Benjamin
Boulware, Ebony
Peterson, Eric D.
Pendergast, Jane
Scialla, Julia
CIRCULATION, 2019, 140
[40] Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
Sharma, Abhinav
Zheng, Yinggan
Ezekowitz, Justin A.
Westerhout, Cynthia M.
Udell, Jacob A.
Goodman, Shaun G.
Armstrong, Paul W.
Buse, John B.
Green, Jennifer B.
Josse, Robert G.
Kaufman, Keith D.
McGuire, Darren K.
Ambrosio, Giuseppe
Chuang, Lee-Ming
Lopes, Renato D.
Peterson, Eric D.
Holman, Rury R.
DIABETES CARE, 2022, 45 (01) : 204 - 212

← 1 2 3 4 5 →